Update: EMA concludes that benefits of AstraZeneca vaccine outweigh the risks


The EMA safety committee held a meeting on 18th March and found that:

  1. the benefits of the vaccine in combating the still widespread threat of COVID-19 (which itself results in clotting problems and may be fatal) continue to outweigh the risk of side effects;
  2. the vaccine is not associated with an increase in the overall risk of blood clots in those who receive it;
  3. there is no evidence of a problem related to specific batches of the vaccine or to particular manufacturing sites;
  4. however, the vaccine may be associated with very rare cases of blood clots associated with thrombocytopenia, i.e. low levels of blood platelets (elements in the blood that help it to clot) with or without bleeding, including rare cases of clots in the vessels draining blood from the brain (CVST).

The full report of the meeting can be found here.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s